Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380816
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-03-27
Brief Title:
A Phase III Trial of UCB4594 in Participants With Advanced Cancer
Sponsor:
Cancer Research UK
Organization:
Cancer Research UK
Study Overview
Official Title:
A Cancer Research UK Phase III Trial to Assess the Safety Tolerability Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial is looking at UCB4594 This is the first time the drug is being tested in humans UCB4594 is a type of drug called a monoclonal antibody It has been designed to work by targeting a protein called human leucocyte antigen G HLA-G that is found in high levels on some cancer cells By attaching itself to this protein it may help the immune system to attack and kill the cancer cells
The four main aims of the clinical trial are to find out
1 The best dose of UCB4594 that can be given safely to participants in the trial
2 What the side effects of UCB4594 are and how they can be managed
3 What happens to UCB4594 inside the body and how it affects cancer cells
4 Whether UCB4594 can cause cancer to shrink
The four main aims of the clinical trial are to find out
1 The best dose of UCB4594 that can be given safely to participants in the trial
2 What the side effects of UCB4594 are and how they can be managed
3 What happens to UCB4594 inside the body and how it affects cancer cells
4 Whether UCB4594 can cause cancer to shrink
Detailed Description:
What does the study involve
This clinical trial is split into two phases
Phase I Module A is the dose escalation phase This is where small groups of participants receive UCB4594 at a certain dose level starting with a low dose level After reviewing the results obtained at each dose level it will be decided whether or how much to increase the dose for the next group of participants This part of the study aims to find the best dose to give that does not cause too many side effects
Phase II is the dose expansion phase This starts when the dose escalation phase has worked out the best dose of UCB4594 to give In this part of the trial UCB4594 will be given alone Module B or in combination with other anti-cancer drugs Module C This will allow us to find out more about how the drug is working and whether UCB4594 affects cancer Details for Module C of the dose expansion phase will be added when the types of cancer and anti-cancer drugs are defined
What are the possible benefits and risks of participating
UCB4594 is a new drug that has never been given to humans before Possible risks and benefits are based on laboratory tests and experience with similar drugs but there is not yet any information about the effects of UCB4594 in humans Participants in the trial will be monitored closely to find out the effects of UCB4594
This clinical trial is split into two phases
Phase I Module A is the dose escalation phase This is where small groups of participants receive UCB4594 at a certain dose level starting with a low dose level After reviewing the results obtained at each dose level it will be decided whether or how much to increase the dose for the next group of participants This part of the study aims to find the best dose to give that does not cause too many side effects
Phase II is the dose expansion phase This starts when the dose escalation phase has worked out the best dose of UCB4594 to give In this part of the trial UCB4594 will be given alone Module B or in combination with other anti-cancer drugs Module C This will allow us to find out more about how the drug is working and whether UCB4594 affects cancer Details for Module C of the dose expansion phase will be added when the types of cancer and anti-cancer drugs are defined
What are the possible benefits and risks of participating
UCB4594 is a new drug that has never been given to humans before Possible risks and benefits are based on laboratory tests and experience with similar drugs but there is not yet any information about the effects of UCB4594 in humans Participants in the trial will be monitored closely to find out the effects of UCB4594
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISRCTN26628699 | REGISTRY | ISRCTN | None |